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Abstract 
Pancreatic cancer is often a fatal disease due to its poor 
response to existing therapies. Thus new therapeutic 
approaches must be developed. The aim of this study 
was to evaluate the susceptibility of pancreatic cell lines 
to adenovirus-mediated transduction and to determine 
the expression of surface coxsackie B and adenovirus 
receptor (CAR). Five human pancreatic cancer cell lines 
were transduced using a recombinant adenovirus type 5 
expressing enhanced green fluorescent protein 
(Ad5EGFP) and the expression of EGFP was analysed 
by flow cytometry. The cell lines varied in transduction 
efficiency, ranging from less than 1% to more than 30% 
cells expressing EGFP and susceptibility of cell lines to 
Ad5EGFP transduction has a positive correlation with 
the level of surface CAR expression and its presence 
may be a limiting step for efficient adenovirus 
transduction. These results suggest that gene therapy of 
pancreatic tumours is feasible, but then the status of 
CAR expression in the tumour needs to be evaluated. 
Keywords: Adenovirus; CAR; pancreatic tumour, gene 
therapy 
 
1. Introduction 
 
Adenovirus (Ad) vectors have been used widely in 
clinical trials for gene transfer [1], especially for the 
treatment of cystic fibrosis [2]. Recently, adenovirus 
gene therapy is being developed to treat cancer patients 
[3].  Since pancreatic cancer is a highly fatal disease 
with only 10% of patients surviving 5 years even when 
conventional treatment can be accomplished [4], the use 
of adenoviruses as therapeutic gene delivery systems 
may offer a new approach to the treatment of pancreatic 
tumours.  However, this requires basic studies of the 
adenovirus entry process in pancreatic tumour cells. 
 
Human adenoviruses, especially those of subgroup 
C such as Ad5, have gained increasing popularity over 
other vector systems as a gene therapy vector due to a 
number of positive attributes of the virus [5] and 
considered to be relatively safe to be used as vectors for 
gene transfer in humans [6].  
Subgroup C adenovirus infection is initiated by 
attachment of the knob domain of the viral fibre protein 
to the human coxsackie B and adenovirus receptor 
(CAR) on the cell surface [7] and internalisation of virus 
into host cell is mediated by secondary interaction 
between the Arg-Gly-Asp motif on penton base protein 
loops and αvβ3 and αvβ5.  Inside the cell cytoplasm, the 
virus escapes its vesicle through the lysis of the 
endosomal and the partially dismantled virus 
translocates to the nuclear pore complex, and releasing 
its genome into the nucleoplasm where subsequent steps 
of viral replication take place [8]. Completion of the 
cycle triggers cell death and the release of progeny 
viruses.  
The capability of an Ad vector to infect a cell is 
depends crucially on the primary (CAR) [9] and 
secondary adenovirus receptors (integrins) expression 
[10]. Because CAR serves as the primary attachment 
molecule for most human adenoviruses, its presence 
may be a limiting step for efficient adenovirus infection.  
CAR expression levels seems to be a limiting step in Ad 
transduction of skeletal muscle [11], endothelial and 
smooth muscle cells [12], brain cells [13], bladder 
cancer cells [14], ovarian cancer [15], human melanoma 
cells cultures [16] and human leukocytes [17]. 
In the present study, we have investigated the 
transduction of five pancreatic tumour cell lines by a 
recombinant adenovirus containing green fluorescent 
protein gene (Ad5EGFP). The level of surface CAR 
expression in pancreatic tumour cell lines has also been 
assessed. We find a strong correlation between the level 
of surface CAR expression and the level of transduction 
of pancreatic tumour cell lines by Ad5EGFP. 
Furthermore, CAR expression level in pancreatic tumour 
cells might be the limiting step in Ad5 transduction. 
This suggests that, in future gene therapy studies of 
pancreatic cancer by adenoviruses, the level of CAR 
expression in the tumour needs to be assessed if 
adenovirus-mediated gene therapy is to be effective. 
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2. Materials and methods 
 
2.1 Adenoviral vectors 
 
Ad5EGFP virus is a replication-deficient 
recombinant Ad5 expressing the enhanced green 
fluorescent protein (EGFP) under the control of the 
cytomegalovirus (CMV) promoter, inserted in place of 
the E1 region. 
 
2.2 Cell culture 
 
Five established human pancreatic tumour cells: 
PSN-1, ASPC-1, Panc-1 and Capan-1 were obtained 
from ECACC, Salisbury, UK and recently-established 
human pancreatic tumour cells NP18 [18] were obtained 
from Dr Ramon Alemany (Institut Catala dOncologia, 
Barcelona, Spain). Human lung carcinoma cells (A549) 
and chinese hamster ovary cells (CHO) were obtained 
from ECACC, Salisbury, UK. All pancreatic and A549 
cells were grown in Dulbeccos modified Eagles 
medium (DMEM) and CHO cells were grown in MEM 
alpha medium. All media were supplemented with 1% 
(v/v) penicillin/streptomycin (10,000 units/ml each), 2% 
(v/v) L-glutamine (2 mM) and 10% (v/v) foetal calf 
serum (FCS) and the cells were maintained at 37ºC in a 
5% CO2 atmosphere. MEM alpha medium was 
purchased from Invitrogen Ltd (Paisley, UK), FCS was 
purchased from LabTech International (East Sussex, 
UK) and DMEM medium and supplements were from 
Sigma-Aldrich Ltd (Poole, UK). 
 
2.3 Flow cytometry analysis 
 
Cells were grown in T75 flasks, harvested by brief 
treatment with trypsin (Sigma-Aldrich Ltd, Poole, UK) 
and resuspended in phosphate-buffered saline (PBS) 
(Sigma-Aldrich Ltd, Poole, UK). Two hundred thousand 
cells were incubated with 50 µl (1:100 dilution) of rabbit 
anti-human CAR [19] or no primary antibody (negative 
control) for 30 minutes at 4ºC. Cells were then washed 
with an excess of PBS and incubated with 50 µl (1:50 
dilution) fluorescein isothiocyanate (FITC)-conjugated 
secondary antibody (Sigma-Aldrich Ltd, Poole, UK) for 
30 min at 4ºC before being washed again with PBS.  
Finally the cells were analysed on a FACScalibur flow 
cytometer (Becton Dickinson, Oxford, UK) using 
CellQuestTM software (Becton Dickinson, Oxford, UK). 
 
2.4 Transduction of cells with Ad5EGFP 
 
Cells (1x105) were grown in 6-well dishes to 
approximately 80-90% confluency before transduction.  
Prior to transduction, the cells were washed twice with 
PBS and then treated with Ad5EGFP at a multiplicity of 
infection (MOI) of 100 focus forming unit (FFU) per 
cell.  After incubation for 1 hour at 37ºC, the cells were 
washed twice with DMEM containing 2% (v/v) FCS and 
fresh DMEM containing 10% (v/v) FCS was added 
before the cells were further incubated for 24 hours at 
37°C.  The cells were then harvested and the EGFP 
expression was assessed by flow cytometry. 
 
3. Results 
 
3.1 Transduction of pancreatic tumour cells by 
recombinant adenovirus expressing green 
fluoresent protein 
 
The recombinant Ad5EGFP virus was used to 
examine the susceptibility of pancreatic tumour cells to 
adenoviral transduction. Since the successfully 
transduced cells can be directly measured by the 
presence of the EGFP transgene, this enabled the 
determination of gene transfer efficiency without 
selection or antibody staining. Conversely, cells resistant 
to adenovirus-based transduction will not express the 
EGFP transgene product. CHO cells have been 
previously described as being resistant to adenovirus 
infection [19] and were used as an example of CAR-
deficient cells (negative control). A549 cells are human 
lung carcinoma cells that are susceptible to adenovirus 
infection and were used to represent CAR-expressing 
cells (positive control).  
A summary of the results of five independent 
analyses in Figure 1 showed that certain cells were 
resistant to adenovirus transduction, whereas others 
were susceptible.  Transduction efficiencies ranged from 
less than 1% to more than 30% of cells.  PSN-1 cell 
lines showed strong resistance to transduction by 
Ad5EGFP (< 1% transduction).  In contrast, the Panc-1 
cell line was most susceptible (35% transduction) to 
transduction by Ad5EGFP, followed by NP18 and 
ASPC-1 and Capan-1.  The control cell line, A549 
showed the highest levels of transduction while CHO 
cells exhibited poor transduction efficiency. Low levels 
of EGFP expression in Ad5EGFP transducted pancreatic 
tumour cells suggests a reduced efficiency of gene 
transfer which could be due to a number of reasons, 
including impaired binding of virus at the plasma 
membrane.  This was investigated further by assaying 
levels of surface receptors for adenoviruses in pancreatic 
tumour cells. 
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Figure 1: Ad5EGFP-mediated transduction in a panel of 
human pancreatic tumour cell lines. A series of pancreatic 
tumour, CHO and A549 cells were transduced by Ad5EGFP a 
recombinant adenovirus containing an enhanced green 
fluorescent protein (EGFP) transgene. Cells were exposed to 
virus at a multiplicity of 100 FFU Ad5EGFP per cell. The 
percentage of EGFP-positive cells was determined by flow 
cytometry at 24 hrs post-transduction.  
 
 
3.2 Expression of the coxsackie B and 
adenovirus receptor (CAR) in pancreatic 
tumour cell lines 
 
Five pancreatic tumour cell lines, CHO and A549 cells 
were analysed for cell surface expression of CAR by 
indirect immunofluorescence assay.  Preliminary 
experiments were performed to ensure that a saturating 
level of anti-CAR antibody was used in all experiments 
(data not shown). Flow cytometric analysis of cell 
surface CAR expression (Figure 2) revealed that it was 
detectable in all of the pancreatic tumour cells. 
 
0
50
100
150
200
250
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 p
er
 c
el
l
C
H
O
A
SP
C
-1
C
ap
an
-1
Pa
nc
-1
PS
N
-1
N
P1
8
Control
CAR expression
A5
49
Cell line
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 p
er
 c
el
l
C
H
O
A
SP
C
-1
C
ap
an
-1
Pa
nc
-1
PS
N
-1
N
P1
8
A5
49
 
 
Figure 2: Expression of CAR cell surface protein in a panel of 
human pancreatic tumour cell lines. Individual pancreatic 
tumour cell lines were analysed by flow cytometry following 
treatment with polyclonal rabbit anti-CAR antibody (1:10 
dilution) and then FITC-labeled goat anti-rabbit 
immunoglobulins secondary antibody (1:50 dilution).  FITC-
labeled anti-rabbit IgG (in the absence of primary antibody) 
was used as a negative control.  
However, expression of CAR varied between 50 to 
more than 150 mean fluorescence intensity (MFI). Panc-
1 and NP 18 cells exhibited a relatively high CAR 
expression of more than 150 MFI per cells, which was 
comparable to A549 cells that formed the positive 
control (160 MFI per cell).  In contrast, PSN-1 cells 
showed rather low CAR expression less than 60 MFI per 
cells.  The remainder of the pancreatic tumour cell lines 
expressed intermediate levels of CAR on the cell 
surface. As expected, CHO cells had or almost no 
detectable surface CAR expression. 
 
3.3 Correlation of CAR expression with 
adenovirus transduction of pancreatic tumour 
cell lines 
 
To examine the correlation between the 
susceptibility of pancreatic tumour cell lines to 
transduction by Ad5EGFP (i.e. the percentage of EGFP-
positive cells) and the expression level of surface CAR 
(i.e the number of adenovirus receptors per cell), the 
level of CAR expression versus the percentage of 
EGFP-positive cells was plotted (Figure 3 and Figure 4) 
and Pearsons statistical analysis was performed using 
SPSS 11.0 software [20].  As shown in Figure 3, it 
seems likely that the lower susceptibility of pancreatic 
tumour cell lines to adenovirus transduction might be 
related to the differences in expression level of CAR, 
because the cell lines with the highest level of CAR 
demonstrated an increase susceptibility to transduction 
with adenovirus and those cell lines with the lowest 
levels of surface CAR were refractory to adenovirus 
transduction.  These data indicated that the level of CAR 
on the cell surface is an important factor in the efficacy 
of gene transfer.   
 
 
C
H
O
A
S P
C
- 1
C
a p
an
- 1
P a
nc
-1
P S
N
-1
N
P1
8
A
54
9
A d 5 E G F P  tra n s d u c t io n
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
1 6 0
1 8 0
C A R  e x p re s s io n
Tr
an
sd
uc
tio
n
(%
EG
FP
 p
os
iti
ve
 c
el
l)
C
A
R
 e
xp
re
ss
io
n
(M
FI
)
C
H
O
A
S P
C
- 1
C
a p
an
- 1
P a
nc
-1
P S
N
-1
N
P1
8
A
54
9T
ra
ns
du
ct
io
n
(%
EG
FP
 p
os
iti
ve
 c
el
l)
C
A
R
 e
xp
re
ss
io
n
(M
FI
)
 
 
Figure 3: Relationship between Ad5EGFP-mediated 
transduction and CAR expression in a panel of human 
pancreatic tumour cell lines. CAR expression (expressed in 
mean fluorescence intensity units, MFI, per cell) was analysed 
using a polyclonal anti-human CAR rabbit antibody and FITC-
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conjugated secondary antibody. All values were calculated 
after deduction of control antibody binding to each cell line.   
Furthermore, if transduction of Ad5EGFP was 
plotted against log MFI of CAR expression it was 
clearly seen that the CAR has to be expressed up to a 
certain limit before a significant transduction could be 
achieved (Figure 4).  
Statistical analysis also demonstrated that there was 
strong significant correlation (r = 0.818; p < 0.01) 
between CAR expression on the cell surface and 
susceptibility of pancreatic tumour cell lines to 
Ad5EGFP transduction. 
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Figure 4: Relationship between percent transduction of 
Ad5EGFP and Log CAR expression in a panel of human 
pancreatic tumour cell lines. Each point represents one cell 
lines and the values were expressed after deduction of control 
antibody binding for each cell line. The expression level of 
CAR in pancreatic tumour cell lines might be a limiting factor 
in adenovirus-mediated transduction due to the fact that the 
CAR has to be expressed up to a certain limit before a 
significant Ad5EGFP transduction could be observed. 
 
3.4 Transgene expression of pancreatic 
tumour cell lines after blocking of cell surface 
CAR 
  
Following the statistical analysis and the fact that 
the expression level of CAR in pancreatic tumour cell 
lines might be a limiting factor in successful 
adenovirus-mediated gene transduction (Figure 3 and 
4), further investigation was performed to evaluate the 
role of CAR in transduction of Ad5EGFP in pancreatic 
tumour cells by blocking experiment i.e blocking the 
attachment of Ad5EGFP to CAR using the polyclonal 
anti-CAR antibody. 
 Results in Figure 5 showed that pre-incubation of 
Panc-1 cells with antibody against CAR reduced 
transgene expression to almost 50% of that control 
(untreated with anti-CAR antibody). Thus, this blocking 
analysis showed that CAR clearly plays an important 
role in adenovirus-mediated gene transfer. 
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Figure 5: Pre-incubation of anti-CAR antibody reduced 
Ad5EGFP transduction of Panc-1 cells. Panc-1 cells were pre-
treated with anti-CAR antibody (1:5 dilution) for 30 minutes 
at 4°C before exposed to 200 FFU per cell of Ad5EGFP virus.  
After 24 hrs of incubation, cells were harvested, and analysed 
by flow cytometry.  Control cells were not treated with anti-
CAR antibody.  A frequency histogram of Panc-1 cells treated 
with anti-CAR antibody showed a strong reduction in 
percentage of EGFP-positive cells. 
 
4. Discussion 
 
Adenovirus gene therapy is an intense area of 
research and is being developed as a therapeutic 
modality for a variety of malignancies[1]. Since 
pancreatic cancer shows a poor response to existing 
treatment, thus there is a great need of new approach to 
overcome this problem. 
Therefore, a study was performed by transducing 
pancreatic tumour cell lines with Ad5EFFP. The 
investigation on the susceptibility of five pancreatic 
tumour cell lines found that all the pancreatic tumour 
cell lines were relatively susceptible to transduction by 
Ad5EGFP (Figure 1). However, PSN-1 pancreatic 
tumour cell lines exhibited strong degree of resistant to 
adenovirus-mediated transduction. Previous studies have 
also shown that certain tumour types and established cell 
lines, for example in human bone marrow cells [21] 
were relatively resistant to adenovirus-mediated gene 
transfer. Furthermore, transduction of Ad5EGFP 
showed a strong correlation (p<0.01) between 
transduction and the level of CAR surface expression in 
each of the cell lines, as determined by flow cytometry 
(Figure 3). Clearly, efficient transduction of pancreatic 
tumour cell lines by Ad5EGFP requires adequate CAR 
expression.  
We also showed that cell surface CAR was 
detected in all of the pancreatic tumour cell lines but 
varied in the level of expression, as shown by flow 
cytometry analysis (Figure 1). This lead to the fact that 
CAR is the primary receptor for Ad5 in pancreatic cells 
in culture, highest level of CAR demonstrated an 
increase susceptibility to transduction with adenovirus 
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and those cell lines with the lowest levels of surface 
CAR were refractory to adenovirus. 
Moreover, investigation on the relative importance 
of receptors as a primary attachment of Ad5EGFP, has 
shown that CAR expression plays a major role in 
limiting transgene expression in pancreatic tumour cell 
lines. In support of this we showed that when CAR 
expression in pancreatic tumour cell lines are blocked by 
anti-CAR antibody, their susceptibility to adenovirus-
mediated gene transfer is markedly reduced as shown by 
blocking experiment (Figure 5). This study is in 
agreement with others studies ([9],[11],[16]). 
 
5.  Conclusion 
 
 The conclusion of this study is that gene therapy of 
pancreatic tumour cells is feasible using Ad-mediated 
gene transfer, and also suggesting that if adenovirus 
vectors are applied to pancreatic cells, the status of CAR 
expression in the tumour needs to be evaluated. In this 
respect, the particular treatment required for pancreatic 
cancer may need to be tailored to the individual patient. 
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